• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Feasibility and surgical outcomes of video‐assisted thoracoscopic pulmonary resection in patients with advanced‐stage lung cancer after neoadjuvant chemoradiotherapy
【24h】

Feasibility and surgical outcomes of video‐assisted thoracoscopic pulmonary resection in patients with advanced‐stage lung cancer after neoadjuvant chemoradiotherapy

机译：Neoadjuvant ChemoRAdiOurapy患者晚期肺癌患者患者视频辅助胸腔镜肺切除的可行性和手术结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Video-assisted thoracoscopic surgery (VATS) is regarded as the standard treatment for lung cancer. However, the feasibility and safety of VATS for lung cancer after neoadjuvant chemoradiotherapy (CRT) is unclear. This study evaluated the feasibility and safety of VATS in patients who had received neoadjuvant CRT. Between January 2008 and December 2017, 85 patients who were administered neoadjuvant CRT and underwent anatomic lung resection were enrolled. Fifty-nine patients underwent open thoracotomy and 26 patients underwent VATS. The clinical characteristics and perioperative outcomes were reviewed. In six of the initial 32 patients who underwent VATS, the procedure was converted to thoracotomy. Adjacent structural invasion (33.9% vs. 11.5%; P?=?0.037) and combined resection (16.9% vs. 0%; P?=?0.025) were higher in the open group than in the VATS group. Surgical duration was higher in the open group than in the VATS group (203.86?±?65.97 vs. 173.27?±?59.87 minutes; P?=?0.046). With regard to postoperative outcomes, the length of the hospital stay was longer in the open group compared to the VATS group (14.46?±?16.94 vs. 8.62?±?4.72?days; P?=?0.017). There was no significant difference in the three-year disease-free survival (69.3% vs. 67.9%; P?=?0.879) or overall survival rates (76.6% vs. 61.9%; P =?0.516). In selected patients, VATS pulmonary resection after neoadjuvant CRT showed results comparable to that of thoracotomy in terms of postoperative outcomes, operative morbidities, and survival rate. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：视频辅助胸镜手术（VALS）被认为是肺癌的标准治疗。然而，Neoadjuvant ChemorAdiotaperapy（CRT）后VATS对肺癌的可行性和安全性尚不清楚。本研究评估了收到Neoadjuvant CRT的患者VATS的可行性和安全性。 2008年1月至2017年12月期间，注册了85名施用Neoadjuvant CRT和接受解剖肺切除的患者。五十九名患者接受开放的胸廓切开术和26例患者受到大桶。综述了临床特征和围手术期结果。在六名初始32名患者中，该程序转化为胸廓切开术。相邻的结构侵袭（33.9％vs.11.5％; p？= 0.037）和组合切除（16.9％与0％; p？= 0.025）比VATS组更高。开放组的外科持续时间比VATS组更高（203.86？±65.97与173.27？±59.87分钟; p？= 0.046）。关于术后结果，与VATS组相比，开放组的住院时间长度更长（14.46？±16.94与8.62？±4.72？天; p？= 0.017）。三年的无病生存率没​​有显着差异（69.3％vs.67.9％; p？= 0.879）或整体存活率（76.6％与61.9％; p = 0.516）。在选定的患者中，Neoadjuvant CRT后VATS肺切除显示结果与胸腔切开术，术后结果，手术病理和生存率相当。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号